Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 7/20 | 1.00 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484152 | 0.92 | CRBN (1.00) | CRBNDDB1SIGMAR1 | |
| SCHEMBL27013181 | 0.86 | CRBN (0.76) | CRBNDDB1MGLLSIGMAR1RIPK1 | |
| SCHEMBL23075787 | 0.85 | CRBN (0.73) | CRBNDDB1MGLL | |
| SCHEMBL22931975 | 0.82 | CRBN (0.82) | CRBNDDB1 | |
| SCHEMBL23075917 | 0.82 | CRBN (0.69) | CRBNDDB1MGLL | |
| SCHEMBL23067577 | 0.81 | CRBN (0.87) | CRBNDDB1 | |
| SCHEMBL23075727 | 0.81 | CRBN (0.67) | CRBNDDB1 | |
| SCHEMBL23067567 | 0.80 | CRBN (0.88) | CRBNDDB1 | |
| SCHEMBL22931974 | 0.80 | CRBN (0.78) | CRBNDDB1 | |
| SCHEMBL2604299 | 0.78 | CRBN (0.71) | CRBNDDB1SIGMAR1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802467-A1 | SPIROCYCLIC COMPOUNDS | C4 Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-119751465-A | Spiro compounds | C4医药公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11623929-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-11623929-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| EP-3802467-A1 | SPIROCYCLIC COMPOUNDS | C4 Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112566886-A | Spiro compounds | C4医药公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885MGLL 4445/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885MGLL 4445/4885 |
| US-11623929-B2 | Spirocyclic compounds | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885MGLL 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.